EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, XOMA Royalty's Enterprise Value is $798.87 Mil.
XOMA Royalty's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $6.79 Mil. Therefore, XOMA Royalty's EV-to-FCF for today is 117.59.
The historical rank and industry rank for XOMA Royalty's EV-to-FCF or its related term are showing as below:
XOMA'
s EV-to-FCF Range Over the Past 10 Years
Min: -243.14 Med: -8.25 Max: 207.37
Current: 117.59
During the past 13 years, the highest EV-to-FCF of XOMA Royalty was 207.37. The lowest was -243.14. And the median was -8.25.
XOMA's EV-to-FCF is ranked worse than 90.66% of 332
companies
in the Biotechnology industry
Industry Median: 16.26
vs XOMA: 117.59
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
XOMA Royalty's PE Ratio (TTM) for today is calculated as:
XOMA Royalty's share price for today is $42.98.
XOMA Royalty's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.570.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
XOMA Royalty EV-to-FCF Related Terms
XOMA Royalty EV-to-FCF Historical Data
* Premium members only.
The historical data trend for XOMA Royalty's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, XOMA Royalty's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XOMA Royalty EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XOMA Royalty's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where XOMA Royalty's EV-to-FCF falls into.
XOMA Royalty's current Enterprise Value is $798.87 Mil.
XOMA Royalty's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.79 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XOMA Royalty (XOMA) has a EV-to-FCF of 117.59 as of Jul. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on XOMA Royalty and its competitors. According to the industry distribution chart, XOMA Royalty ranks #301 out of 332 companies in the Biotechnology industry, placing it in the top 90.7%.
Is XOMA Royalty's EV-to-FCF too high?
XOMA Royalty's current EV-to-FCF is 117.59. The Biotechnology industry median EV-to-FCF is 16.26. XOMA Royalty's value of 117.59 is 623.2% above this industry median. Based on the distribution chart, XOMA Royalty ranks #301 out of 332 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, XOMA Royalty has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does XOMA Royalty's EV-to-FCF compare to CLYM and CTMX?
According to the Biotechnology industry distribution chart, XOMA Royalty ranks #301 out of 332 companies for EV-to-FCF. This places XOMA Royalty in the lower half of its industry. The industry median EV-to-FCF is 16.26. XOMA Royalty's value of 117.59 is 623.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.26, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. XOMA Royalty's current EV-to-FCF of 117.59 is 623.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on XOMA Royalty and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. XOMA Royalty's current EV-to-FCF is 117.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XOMA Royalty stock overvalued right now?
Based on GuruFocus' analysis, XOMA Royalty (XOMA) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.87, compared to a current price of $42.98 — trading 127.8% above its estimated fair value. The current EV-to-FCF is 117.59 and 623.2% above the Biotechnology industry median of 16.26. XOMA Royalty's overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For XOMA Royalty (XOMA), the current EV-to-FCF is 117.59 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is XOMA Royalty (XOMA) Overvalued in 2026?
Based on GuruFocus' analysis, XOMA Royalty stock appears to be overvalued.
The current stock price of $42.98 is trading 127.8% above its estimated GF Value™ of $18.87.
GuruFocus considers XOMA Royalty to be Significantly Overvalued.
Key valuation signals for XOMA:
EV-to-FCF: 117.59
GF Value™: $18.87 vs. price of $42.98 (127.8% above fair value)
Industry Position: 623.2% above the Biotechnology median (#301 of 332)
No single metric tells the full story. See the XOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
45GF Score
Get the complete analysis for XOMA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XOMA has been successfully added to your 
